Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
DynPort Vaccine Company LLC, A CSC Company |
---|---|
Information provided by: | DynPort Vaccine Company LLC, A CSC Company |
ClinicalTrials.gov Identifier: | NCT00057525 |
This study will provide preliminary safety and comparative immunogenicity data for the E.coli derived rPA vaccine administered by intramuscular (IM) injection at Day 0 and Month 1.Doses will range from 5 μg to 100 μg rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel.
Condition | Intervention | Phase |
---|---|---|
Anthrax |
Biological: Vaccine |
Phase I |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety Study |
Official Title: | A Phase 1 Study of Safety and Immunogenicity of E. Coli-Derived Recombinant Protective Antigen (rPA), a New Anthrax Vaccine Administered by the Intramuscular (IM) Route in Healthy Adults |
Estimated Enrollment: | 70 |
Study Start Date: | April 2003 |
Estimated Study Completion Date: | April 2004 |
This is a safety study with an open-label part (2 groups), followed by a dose-ranging part evaluating safety and immunogenicity using a double-blind, sequential-group design with randomization and placebo-control within each of the 6 groups. Volunteers in each dose group will receive two IM injections at Day 0 and Month 1
Ages Eligible for Study: | 18 Years to 40 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Volunteers are eligible for this study if they meet all the following criteria:
Normal Baseline Clinical Laboratory Values at screening including:
United States, Maryland | |
Walter Reed Army Institute of Research / Henry M. Jackson Foundation Vaccine Clinical Research Center, 1600 East Gude Dr | |
Rockville, Maryland, United States, 20850 |
Principal Investigator: | Merlin L Robb, MD | Walter Reed Army Institute of Research / Henry M. Jackson Foundation Vaccine Clinical Research Center, 1600 East Gude Dr., Rockville, MD 20850 |
Study ID Numbers: | rPA-EC-02, Anthrax |
Study First Received: | April 3, 2003 |
Last Updated: | January 25, 2007 |
ClinicalTrials.gov Identifier: | NCT00057525 |
Health Authority: | United States: Food and Drug Administration |
Anthrax |
Bacterial Infections Gram-Positive Bacterial Infections Anthrax Healthy |
Bacillaceae Infections |